NBTY to Acquire Solgar
07 Giugno 2005 - 2:00PM
PR Newswire (US)
NBTY to Acquire Solgar BOHEMIA, N.Y., June 7 /PRNewswire-FirstCall/
-- NBTY, Inc. (NYSE:NTY) (http://www.nbty.com/), a leading global
manufacturer and marketer of nutritional supplements, today
announced it has signed a contract to acquire, for $115 million,
substantially all the assets of Solgar Vitamin and Herb, a division
of Wyeth Consumer Healthcare (Wyeth NYSE: WYE). Solgar(R), a
prominent supplement company established in 1947, had sales for
2004 of approximately $105 million. Included in the acquisition are
net assets of approximately $64 million. The purchase price will be
adjusted based upon the actual net assets transferred at closing.
The transaction is subject to regulatory and other customary
approvals and is expected to close by August 2005. Solgar(R)
manufactures and distributes premium-branded nutritional
supplements including multivitamins, minerals, botanicals and
specialty formulas designed to meet the specific needs of men,
women, children and seniors. Solgar's headquarters and major
manufacturing facility are located in Bergen County, New Jersey.
Solgar's products are sold at nearly 5,000 health food stores,
natural product stores, natural pharmacies and specialty stores
across the United States. In addition, Solgar's products are sold
internationally in 40 countries including North and South America,
Asia, the Middle East, Europe, South Africa, Australia and New
Zealand. NBTY Chairman and CEO Scott Rudolph, said, "Solgar will
strengthen NBTY's presence in the health food store market. The
Solgar brand will be focused on serving the needs of the
independent health food store across the United States. It is a
significant opportunity for NBTY to grow both domestically and
internationally." Banc of America Securities LLC acted as the sole
financial advisor to NBTY. ABOUT NBTY NBTY is a leading vertically
integrated manufacturer and distributor of a broad line of
high-quality, value-priced nutritional supplements in the United
States and throughout the world. The Company markets approximately
2,000 products under several brands, including Nature's Bounty(R),
Vitamin World(R), Puritan's Pride(R), Holland & Barrett(R),
Rexall(R), Sundown(R), MET-Rx(R), WORLDWIDE Sport Nutrition(R),
American Health(R), GNC (UK)(R), DeTuinen(R) and Le Naturiste(TM).
This release contains certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
with respect to our financial condition, results of operations and
business. All of these forward-looking statements, which can be
identified by the use of terminology such as "subject to,"
"believe," "expects," "plan," "project," "estimate," "intend,"
"may," "will," "should," "can," or "anticipates," or the negative
thereof, or variations thereon, or comparable terminology, or by
discussions of strategy which, although believed to be reasonable,
are inherently uncertain. Factors which may materially affect such
forward-looking statements include: (i) slow or negative growth in
the nutritional supplement industry; (ii) interruption of business
or negative impact on sales and earnings due to acts of war,
terrorism, bio-terrorism, civil unrest or disruption of mail
service; (iii) adverse publicity regarding nutritional supplements;
(iv) inability to retain customers of companies (or mailing lists)
recently acquired; (v) increased competition; (vi) increased costs;
(vii) loss or retirement of key members of management; (viii)
increases in the cost of borrowings and/or unavailability of
additional debt or equity capital; (ix) unavailability of, or
inability to consummate, advantageous acquisitions in the future,
including those that may be subject to bankruptcy approval or the
inability of NBTY to integrate acquisitions into the mainstream of
its business; (x) changes in general worldwide economic and
political conditions in the markets in which NBTY may compete from
time to time; (xi) the inability of NBTY to gain and/or hold market
share of its wholesale and/or retail customers anywhere in the
world; (xii) unavailability of electricity in certain geographical
areas; (xiii) the inability of NBTY to obtain and/or renew
insurance and/or the costs of the same; (xiv) exposure to and
expense of defending and resolving, product liability claims and
other litigation; (xv) the ability of NBTY to successfully
implement its business strategy; (xvi) the inability of NBTY to
manage its retail, wholesale, manufacturing and other operations
efficiently; (xvii) consumer acceptance of NBTY's products; (xviii)
the inability of NBTY to renew leases for its retail locations;
(xix) inability of NBTY's retail stores to attain or maintain
profitability; (xx) the absence of clinical trials for many of
NBTY's products; (xxi) sales and earnings volatility and/or trends
for the Company and its market segments; (xxii) the efficacy of
NBTY's Internet and on-line sales and marketing; (xxiii)
fluctuations in foreign currencies, including the British Pound and
the euro; (xxiv) import-export controls on sales to foreign
countries; (xxv) the inability of NBTY to secure favorable new
sites for, and delays in opening, new retail locations; (xxvi)
introduction of and compliance with new federal, state, local or
foreign legislation or regulation or adverse determinations by
regulators anywhere in the world (including the banning of
products) and more particularly proposed Good Manufacturing
Practices in the United States, the Food Supplements Directive and
Traditional Herbal Medicinal Products Directive in Europe and
Section 404 requirements of the Sarbanes- Oxley Act of 2002;
(xxvii) the mix of NBTY's products and the profit margins thereon;
(xxviii) the availability and pricing of raw materials; (xxix) risk
factors discussed in NBTY's filings with the U.S. Securities and
Exchange Commission; (xxx) adverse effects on NBTY as a result of
increased gasoline prices and potentially reduced traffic flow to
NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii)
the loss of a significant customer of the Company; and (xxxiii)
other factors beyond the Company's control. NBTY cannot be certain
that the measures taken will be sufficient to meet the section 404
requirements of the Sarbanes-Oxley Act of 2002. Readers are
cautioned not to place undue reliance on forward-looking
statements. NBTY cannot guarantee future results, trends, events,
levels of activity, performance or achievements. NBTY does not
undertake and specifically declines any obligation to update,
republish or revise forward- looking statements to reflect events
or circumstances after the date hereof or to reflect the
occurrences of unanticipated events. Consequently, such
forward-looking statements should be regarded solely as NBTY's
current plans, estimates and beliefs. DATASOURCE: NBTY, Inc.
CONTACT: Harvey Kamil, President & Chief Financial Officer of
NBTY, Inc., +1-631-200-2020; or Carl Hymans of G.S. Schwartz &
Co., +1-212-725- 4500, , for NBTY, Inc. Web site:
http://www.nbty.com/
Copyright
Grafico Azioni N B T Y (NYSE:NTY)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni N B T Y (NYSE:NTY)
Storico
Da Lug 2023 a Lug 2024